Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019 - Takashita, Emi; Ichikawa, Masataka; Morita, Hiroko; Ogawa, Rie; Fujisaki, Seiichiro; Shirakura, Masayuki; Miura, Hideka; Nakamura, Kazuya; Kishida, Noriko; Kuwahara, Tomoko; Sugawara, Hiromi; Sato, Aya; et al. (Emerging infectious diseases, 2019)
Keywords: Adolescent; Adult; antimicrobial resistance; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; baloxavir acid; Baloxavir marboxil; cap-dependent endonuclease inhibitor; Child; Clinical trials; Disease Susceptibility; Dispatch; drug resistance; Genes; Genomes; Genomics; Humans; Infant; Infection; Influenza; Influenza A Virus, H3N2 Subtype - drug effects; Influenza A Virus, H3N2 Subtype - genetics; influenza virus; Influenza viruses; Influenza, Human - drug therapy; Influenza, Human - epidemiology; Influenza, Human - transmission; Influenza, Human - virology; Japan - epidemiology; Laninamivir; Middle Aged; Mutation; Nucleases; Oxazines - pharmacology; Oxazines - therapeutic use; Peramivir; Pyridines - pharmacology; Pyridines - therapeutic use; Thiepins - pharmacology; Thiepins - therapeutic use; Triazines - pharmacology; Triazines - therapeutic use; Young Adult; Japan; influenza; viruses; Japan; whole-genome sequencing; baloxavir; H3N2; respiratory infections; influenza A(H1N1)pdm09; baloxavir marboxil; I38T substitution; antimicrobial resistance; polymerase acidic; family cluster; influenza virus; cap-dependent endonuclease inhibitor; baloxavir acid; human-to-human transmission